摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,4-dihydroindeno[1,2-c]pyrazole-7-carbaldehyde | 866851-93-6

中文名称
——
中文别名
——
英文名称
1,4-dihydroindeno[1,2-c]pyrazole-7-carbaldehyde
英文别名
1,4-Dihydroindeno[1,2-c]pyrazole-7-carbaldehyde
1,4-dihydroindeno[1,2-c]pyrazole-7-carbaldehyde化学式
CAS
866851-93-6
化学式
C11H8N2O
mdl
——
分子量
184.197
InChiKey
HBDHMPRWWTUUEM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    452.3±33.0 °C(Predicted)
  • 密度:
    1.400±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    45.8
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: Extended exploration on phenyl ring substitutions and preliminary ADME/PK studies
    摘要:
    A study on substitutions at the four open positions on the phenyl ring of the 1,4-dihydroindeno[1,2-c]pyrazoles as potent CHK-1 inhibitors is described. Bis-substitution at both the 6- and 7-positions led to inhibitors with IC50 values below 0.3 nM. The compound with the best overall activities (36) was able to potentiate the anti-proliferative effect of doxorubicin in HeLa cells by at least 47-fold. Physicochemical, metabolic, and pharmacokinetic properties of selected inhibitors are also disclosed. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.04.055
  • 作为产物:
    描述:
    7-Bromo-1,4-dihydroindeno[1,2-c]pyrazole 、 N,N-二甲基甲酰胺仲丁基锂苯基锂 作用下, 以 四氢呋喃 为溶剂, 生成 1,4-dihydroindeno[1,2-c]pyrazole-7-carbaldehyde
    参考文献:
    名称:
    1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: Extended exploration on phenyl ring substitutions and preliminary ADME/PK studies
    摘要:
    A study on substitutions at the four open positions on the phenyl ring of the 1,4-dihydroindeno[1,2-c]pyrazoles as potent CHK-1 inhibitors is described. Bis-substitution at both the 6- and 7-positions led to inhibitors with IC50 values below 0.3 nM. The compound with the best overall activities (36) was able to potentiate the anti-proliferative effect of doxorubicin in HeLa cells by at least 47-fold. Physicochemical, metabolic, and pharmacokinetic properties of selected inhibitors are also disclosed. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.04.055
点击查看最新优质反应信息

文献信息

  • [EN] FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRAZOLE KINASE FUSIONNEE TRICYCLIQUE ET TETRACYCLIQUE
    申请人:ABBOTT LAB
    公开号:WO2004080973A1
    公开(公告)日:2004-09-23
    Compounds having the formula (I) (I), are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    具有化学式(I) (I)的化合物对抑制蛋白激酶很有用。还公开了制备这些化合物的方法、含有这些化合物的组合物,以及使用这些化合物进行治疗的方法。
  • Fused tri and tetra-cyclic pyrazole kinase inhibitors
    申请人:——
    公开号:US20040259904A1
    公开(公告)日:2004-12-23
    Compounds having the formula (I) 1 are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    化合物具有公式(I)1,对于抑制蛋白激酶具有用途。还公开了制备该化合物的方法,含有该化合物的组合物以及使用该化合物的治疗方法。
  • Tricyclic pyrazole kinase inhibitors
    申请人:Arnold D. Lee
    公开号:US20060014816A1
    公开(公告)日:2006-01-19
    Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    本发明的化合物可用于抑制蛋白酪氨酸激酶。还公开了制备该化合物的方法,含有该化合物的组合物,以及使用该化合物的治疗方法。
  • FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS
    申请人:ABBOTT LABORATORIES
    公开号:EP1603885A1
    公开(公告)日:2005-12-14
  • TRICYCLIC PYRAZOLE KINASE INHIBITORS
    申请人:AbbVie Inc.
    公开号:EP1740579B1
    公开(公告)日:2015-08-19
查看更多